/

Karyopharm Therapeutics Inc.

KPTI US

KPTI USKaryopharm Therapeutics Inc.

United States Composite

1.06

USD

- -

-1.25EPS Dil.

-0.85P/E

121.81MMarket Cap

Next Earnings

May 2

Held by Insiders

6.06%

Held by Institutions

68.36%

Short % of Float

20.37%

YTD Yield

-56.86%

3Y Yield

-84.34%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

LT Borrowings

170

171

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

114

115

Market Capitalization

205

153

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

291

263

234

Cash, Cash Equivalents & STI

237

208

191

Accounts Receivable, Net

Inventories

Total Current Liabilities

Payables & Accruals

ST Debt

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

0.00%

52.46%

-7.01%

Net Income, GAAP

-22.06%

1.33%

13.33%

Free Cash Flow

-21.78%

6.45%

38.00%

Total Cash Common Dividend

- -

Total Equity

-91.63%

-189.76%

-700.00%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

126

210

2022

157

2023

146

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-0.77

-0.71

-0.69

0.51

-1.65

2022

-0.53

-0.62

-0.45

-0.43

-2.02

2023

-0.30

-0.29

-0.30

-0.36

-1.25

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Mr. Richard A. Paulson M.B.A.
Full Time Employees: 325
Sector: Healthcare
Industry: Biotechnology
Address: 85 Wells Avenue Newton MA United States 02459-3298
CIK: 0001503802
Website: www.karyopharm.com
Business: Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Company News

Yahoo
3 days ago
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
Yahoo
a month ago
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo
2 months ago
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
Tipranks
2 months ago
Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (KPTI) and Siemens Healthineers AG (OtherSEMHF)
Yahoo
2 months ago
Insider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ...

Company News

Yahoo
3 days ago
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
Yahoo
a month ago
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo
2 months ago
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
Tipranks
2 months ago
Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (KPTI) and Siemens Healthineers AG (OtherSEMHF)
Yahoo
2 months ago
Insider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ...

Company Description

CEO: Mr. Richard A. Paulson M.B.A.
Full Time Employees: 325
Sector: Healthcare
Industry: Biotechnology
Address: 85 Wells Avenue Newton MA United States 02459-3298
CIK: 0001503802
Website: www.karyopharm.com
Business: Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.